Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 5/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509065 | 0.93 | S1PR1 (0.68) | S1PR1NPC1RAB9ATP53MAPT | |
| SCHEMBL4522443 | 0.92 | S1PR1 (0.53) | S1PR1NPC1RAB9ATP53MAPT | |
| SCHEMBL3880443 | 0.89 | S1PR1 (0.56) | S1PR1NPC1RAB9ATP53MAPT | |
| SCHEMBL4522469 | 0.88 | TP53 (0.61) | S1PR1TP53MAPTMAOBMAOA | |
| SCHEMBL3889523 | 0.86 | S1PR1 (0.67) | S1PR1TP53MAPTMAOBMAOA | |
| SCHEMBL3888542 | 0.85 | S1PR1 (0.77) | S1PR1RAB9ATP53MAPTMAOB | |
| SCHEMBL3880616 | 0.85 | S1PR1 (0.62) | S1PR1NPC1RAB9ATP53MAPT | |
| SCHEMBL4510482 | 0.85 | S1PR1 (0.52) | S1PR1NPC1RAB9ATP53MAPT | |
| SCHEMBL3881451 | 0.84 | S1PR1 (0.65) | S1PR1NPC1TP53MAPTMAOB | |
| SCHEMBL3880113 | 0.82 | S1PR1 (0.62) | S1PR1TP53MAPTMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | claimed |
| EP-2010511-A1 | CHROMEN-2-ONE DERIVATIVES | Novartis AG (CH) | 2009-01-07 | — | — | EP | claimed |
| WO-2007115820-A1 | CHROMEN-2-ONE DERIVATIVES | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | S1PR1 3084/4885NPC1 1757/4885RAB9A 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.